Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

3186studies shown

Showing 2,401-2,425 of 3,186

CompletedNCT06880328

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 50 Years

Countries: United States
Sponsor: Hoffmann-La Roche
Condition: Schizophrenia

CompletedNCT02237417

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

This study exists to compare options and see whether brain scans or other body measurements offers something meaningfully different. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 35 Years

Countries: United States
Sponsor: University of Utah
Condition: Schizophrenia

CompletedNCT02085421

Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years

Countries: United States
Sponsor: University of Minnesota
Condition: Schizophrenia

CompletedNCT04005794

Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Vanderbilt University
Condition: Schizophrenia

CompletedNCT03076346

Neural Biomarkers of Clozapine Response

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 50 Years

Countries: United States
Sponsor: University of Pittsburgh
Condition: Schizophrenia

WithdrawnNCT05890768

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

This study exists to compare options and see whether a therapy or guided support program offers something meaningfully different. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 40 Years

Countries: United States
Sponsor: University of New Mexico
Condition: Schizophrenia

CompletedNCT05953740

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

This study exists to better understand the safety of the medication MK-5720 and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication MK-5720 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 60 Years

Countries: United States
Sponsor: Merck Sharp & Dohme LLC
Condition: Schizophrenia

CompletedNCT05032963

Neurocognition After Perturbed Sleep

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years

Countries: United States
Sponsor: Icahn School of Medicine at Mount Sinai
Condition: Schizophrenia

CompletedNCT01569659

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

This study exists to compare options and see whether blood tests and biological markers offers something meaningfully different. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years

Countries: United States
Sponsor: Northwestern University
Condition: Schizophrenia

CompletedNCT05746494

The Efficacy of Neural Stimulation in Individuals With Schizophrenia

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 64 Years

Countries: United States
Sponsor: The University of Texas at Dallas
Condition: Schizophrenia

CompletedNCT02118571

Schizophrenia Cognition Scale Development

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years

Countries: United States
Sponsor: Carelon Research
Condition: Schizophrenia

RecruitingNCT04414215

Cognitive Training for Emotion Regulation in Psychotic Disorders

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years

Countries: United States
Sponsor: University of Georgia
Condition: Schizophrenia

Active Not RecruitingNCT00179465

Treating Schizophrenia by Correcting Abnormal Brain Development

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 25 Years

Countries: United States
Sponsor: Beth Israel Deaconess Medical Center
Condition: Schizophrenia

CompletedNCT01992913

Building Employment Skills Through Therapy for Veterans

This study exists to compare options and see whether cognitive behavioural therapy, a structured talking treatment, offers something meaningfully different. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: VA Office of Research and Development
Condition: Schizophrenia

CompletedNCT00490516

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

This study exists to compare options and see whether the medication ACP-104 offers something meaningfully different. Researchers are trying to understand what the medication ACP-104 could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 60 Years

Countries: United States
Sponsor: ACADIA Pharmaceuticals Inc.
Condition: Schizophrenia

CompletedNCT05207982

Weight Management Program for Patients With First Episode Psychosis

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can better support energy, concentration, and everyday functioning.

SchizophreniaOtherFrom 14 Years to 26 Years

Countries: United States
Sponsor: State University of New York at Buffalo
Condition: Schizophrenia

Active Not RecruitingNCT04783571

Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years

Countries: United States
Sponsor: Massachusetts General Hospital
Condition: Schizophrenia

CompletedNCT06486948

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

This study exists to see whether the medication CT-156 is workable and worth testing more broadly. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherOver 18 Years

Countries: United States
Sponsor: Click Therapeutics, Inc.
Condition: Schizophrenia

CompletedNCT04418466

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

This study exists to better understand the safety of a digital app or remote support tool and how manageable it feels in practice. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 70 Years

Countries: United States
Sponsor: Delpor, Inc.
Condition: Schizophrenia

RecruitingNCT05184335

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This study exists to understand how a medication treatment holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Reviva Pharmaceuticals
Condition: Schizophrenia

CompletedNCT05746455

Motivation Skills Training for Schizophrenia

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Columbia University
Condition: Schizophrenia

RecruitingNCT04038840

Imaging Synapses With [11C] UCB-J in the Human Brain

This study exists to improve how brain scans or other body measurements can help identify, measure, or follow care over time. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Davidzon, Guido, M.D.
Condition: Schizophrenia

TerminatedNCT04109950

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 13 Years to 65 Years

Countries: Bulgaria, Colombia, Croatia, Latvia, Russian Federation, Serbia, Ukraine, United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

CompletedNCT00254202

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: India, United States
Sponsor: Vanda Pharmaceuticals
Condition: Schizophrenia

CompletedNCT04738123

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: Ukraine, United States
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia